Podomatic: Paul-Peter Tak
In biotech, DR. PAUL-PETER TAK, the CEO of Kintai Therapeutics gives us a bigger picture of our gut – it’s not just your microbiome that plays a significant role in the recovery from illness.
Lis…
Bios Appoints Biotech Leader Paul Peter Tak, MD PHD as a Strategic Advisor
Cambridge, UK and Montreal, Canada – 5 May, 2021 – BIOS Health, a pioneer in the development of neural interfaces, has appointed world-renowned immunologist and biotechnology business leader, Paul P…
GSK Funds a New Startup with Immunometabolic Focus
Backed by GlaxoSmithKline and Boston’s SV Health Investors, a new biopharmaceutical company known as Sitryx launched with $30 million in a Series A funding round to develop disea…
EXCLUSIVE: Flagship Pioneering Company Kintai Therapeutics Focuses on Enteric Therapeutics
The vast majority of immune cells are found in the gut but historically, the gut has been viewed as a liability to drug development. The question of whether or not greater understanding of harnessin…
Industry veterans Paul Peter Tak and Eric Meldrum join Citryll’s Board
Citryll announced its Board has been strengthened with two industry veterans with impressive track-records.
Who is Paul-Peter Tak?
Paul Peter Tak, MD, PhD served as Professor of Medicine and C…
Candel Therapeutics Appoints Pharma Veteran And Immunologist Paul-Peter Tak, M.D, PH.D. as CEO
Candel Therapeutics appoints Pharma veteran and immunologist Paul-Peter Tak, M.D., PH.D., as Chief Executive Officer, expands leadership team with Chief Financial Officer, Chief Business Officer and…
